After the majority of pharmaceutical companies released their earnings reports for 2022, we released our annual Pharma 50 feature detailing how the pharma landscape has evolved. Four of the five most popular pieces of content on Drug Discovery & Development were part of the Pharma 50 feature.
In the past year, Pfizer (NYSE:PFE) cemented its position as the biggest pharma company, thanks in large part to strong sales of its COVID-19 products in 2021, but its stock price lost about 10% of its value over the course of 2022. Meanwhile, the Dow Jones U.S. Pharmaceuticals Index was down close to 6% while the S&P Pharmaceuticals Select Industry Index fell almost 13% in 2022.
The COVID-19 vaccine from Pfizer and BioNTech was far and away the most popular product of 2021.
Strong demand for COVID-19 therapies resulted in a dramatically different pharmaceutical industry landscape and a dramatically different Pharma 50 list of the largest pharmaceutical companies from the year before.
Although generally well-tolerated, the Jynneos vaccine can have significant adverse events in a limited number of individuals.
Sage Therapeutics was once again the top-ranked pharmaceutical employer.
Our new ranking of cell and gene therapy companies on Drug Discovery & Development is among the most popular on our site.
Most popular Drug Discovery & Development content on social media in 2022
The following articles gained the most traction on LinkedIn.
Late in the year, Eli Lilly and Company announced that it successfully completed its acquisition of Akouos, expanding its efforts in genetic medicines.
An executive at Kyowa Kirin North America (KKNA) opened up about the company’s efforts to address the racial disparities affecting the care and outcomes of African American patients with Cutaneous T-cell Lymphoma (CTCL).
Drug Discovery & Development interviewed the CEO of the proteomics company Seer (Nasdaq:SEER), which has a growing roster of customers, including pharma and biotech companies.
The psychedelic therapy company MindMed announced upbeat results from a Phase 2 study focused on patients with anxiety.
Another article on MindMed documents the dosing of the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD).
Filed Under: Cell & gene therapy, Drug Discovery and Development, Oncology